Sox Therapeutics was founded in 2025 and is developing targeted gene therapies for malignant brain tumors. The therapies are innovative and based on tailored adeno-associated viral (AAV) approaches. The treatments are developed based on important findings from two decades of intense research at Uppsala University on how therapy resistance develops in patients with brain cancer.

FREDRIK Swartling

Chief Executive Officer, Founder

Board Member

Professor,
Uppsala University, Sweden

Mateo Santurio

Board Member

Business Advisor

christina herder

Board Member (chair)

Business Advisor

Tina LIN

Scientific Researcher

Viral Vector Design 

tobias bergström

Clinical Study Lead

Clinical Study Coordinator

ANNIKA JOHANSSON

AAV gene therapy expert

CMC Drug Development

SONJA HUTTER

Co-Inventor, Scientific Advisor

Clinical Diagnostics and Genetics

Mats hellström

Medical Advisor

Adult Brain Tumor Treatment

and Immunotherapies